What is the EyePoint Pharmaceuticals Inc. stock price forecast?

EyePoint Pharmaceuticals Inc. is currently trading at $13.03. View real-time AI analysis on Alpha Lenz.

What is EyePoint Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for EyePoint Pharmaceuticals Inc. on Alpha Lenz.

What is EyePoint Pharmaceuticals Inc.'s P/E ratio?

EyePoint Pharmaceuticals Inc.'s P/E ratio is -4.1.

EyePoint Pharmaceuticals Inc.

NASDAQ · EYPT

$13.03+0.53(+4.24%)Pre-market

Ask about EyePoint Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“EyePoint Pharmaceuticals Inc. trades at a P/E of -4.1 (undervalued) with modest ROE of -72.2%.”

Ask for details →

Company Overview

EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. EyePoint's unique approach leverages drug delivery technologies which offer sustained-release treatments, enhancing patient outcomes by providing consistent therapeutic levels over extended periods. The company operates within the biotechnology and healthcare sectors, impacting the pharmaceutical landscape by addressing unmet medical needs in ophthalmology. EyePoint Pharmaceuticals plays a significant role in the market through collaborations with leading eye care companies, advancing therapeutic research and expanding access to novel solutions for visual impairment. Based in Watertown, Massachusetts, the company continues to innovate and lead in the field of ocular drug development, contributing to the advancement of vision-related healthcare on a global scale.

CEODr. Jay S. Duker M.D.

Websitehttps://eyepointpharma.com

SectorHealthcare

IndustryBiotechnology

Employees165

Company Statistics

FY 2025

Profile

$954.46MMarket Cap

$31.37MRevenue

0.00Shares Out

165Employees

Margins

93.41%Gross

-731.06%EBITDA

-775.98%Operating

-738.53%Pre-Tax

-739.42%Net

Valuation

-4.11P/E

3.12P/B

30.42EV/Sales

-3.81EV/EBITDA

-3.92P/FCF

Growth (CAGR)

-8.83%Rev 3Yr

-1.85%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-59.29%ROA

-72.19%ROE

-59.21%ROIC

Financial Health

$101.82MCash & Cash Equivalents

$-43.94MNet Debt

18.91%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“EyePoint Pharmaceuticals Inc. trades at a P/E of -4.1 (undervalued) with modest ROE of -72.2%.”

Ask for details →

Frequently Asked Questions

EyePoint Pharmaceuticals Inc. (ticker: EYPT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 165 employees. Market cap is $954M.

The current price is $13.03 with a P/E ratio of -4.11x and P/B of 3.12x.

ROE is -72.19% and operating margin is -775.98%. Annual revenue is $31M.